1foz: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
|PDB= 1foz |SIZE=350|CAPTION= <scene name='initialview01'>1foz</scene> | |PDB= 1foz |SIZE=350|CAPTION= <scene name='initialview01'>1foz</scene> | ||
|SITE= | |SITE= | ||
|LIGAND= <scene name='pdbligand=ACE:ACETYL GROUP'>ACE</scene> | |LIGAND= <scene name='pdbligand=ACE:ACETYL+GROUP'>ACE</scene> | ||
|ACTIVITY= | |ACTIVITY= | ||
|GENE= | |GENE= | ||
|DOMAIN= | |||
|RELATEDENTRY= | |||
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1foz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=1foz OCA], [http://www.ebi.ac.uk/pdbsum/1foz PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=1foz RCSB]</span> | |||
}} | }} | ||
| Line 26: | Line 29: | ||
[[Category: Mierke, D F.]] | [[Category: Mierke, D F.]] | ||
[[Category: Pellegrini, M.]] | [[Category: Pellegrini, M.]] | ||
[[Category: irma refinement]] | [[Category: irma refinement]] | ||
[[Category: ribonucleotide reductase inhibitor]] | [[Category: ribonucleotide reductase inhibitor]] | ||
[[Category: transferred no]] | [[Category: transferred no]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun Mar 30 20:27:17 2008'' | ||
Revision as of 17:27, 30 March 2008
| |||||||||||||
| 1foz | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ligands: | ACE | ||||||||||||
| Resources: | FirstGlance, OCA, PDBsum, RCSB | ||||||||||||
| Coordinates: | save as pdb, mmCIF, xml | ||||||||||||
STRUCTURE OF CYCLIC PEPTIDE INHIBITORS OF MAMMALIAN RIBONUCLEOTIDE REDUCTASE
Overview
Mammalian ribonucleotide reductase (mRR), a potential target for cancer intervention, is composed of two subunits, mR1 and mR2, whose association is critical for enzyme activity. In this article we describe the structural features of the mRR-inhibitor Ac-F-c[ELAK]-DF (Peptide 3) while bound to the mR1 subunit as determined by transferred NOEs. Peptide 3 is a cyclic analogue of the N-acetylated form of the heptapeptide C-terminus of the mR2 subunit (Ac-FTLDADF), which is the link between the two subunits and previously shown to be the minimal sequence inhibitor mRR by competing with mR2 for binding to mR1. Structural refinement employing an ensemble-based, full-relaxation matrix approach resulted in two structures varying in the conformations of F(1) and the cyclic lactam side chains of E(2) and K(5). The remainder of the molecule, both backbone and side chains, is extremely well-defined, with an RMSD of 0.54 A. The structural features of this conformationally constrained analogue provide unique insight into the requirements for binding to mR1, critical for further inhibitor development.
About this Structure
1FOZ is a Protein complex structure of sequences from [1]. Full crystallographic information is available from OCA.
Reference
Structure-based optimization of peptide inhibitors of mammalian ribonucleotide reductase., Pellegrini M, Liehr S, Fisher AL, Laub PB, Cooperman BS, Mierke DF, Biochemistry. 2000 Oct 10;39(40):12210-5. PMID:11015199
Page seeded by OCA on Sun Mar 30 20:27:17 2008
